Lydia Carpenter, MD
Dermatology · Valencia
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 24 years
- Harvard Medical School, 2002
Offices
1 location · Skin and Beauty Center Inc · 34 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Carpenter’s office at (661) 258-3811 to ask if they take your plan before you enroll.
California Medical Board record
Licence A84038 · Current
Licensed to practise in California · since 2003 · expires 2028-10-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Original Medicare doctor bills
$59,176
Medicare paid this office $59,176 for 207 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 106 | $9,778 | $69 |
| Return visit (30+ min) | 67 | $9,151 | $92 |
| Destruction of skin growth, 1-14 growths | 62 | $7,060 | $89 |
| Biopsy of related skin growth, first growth | 56 | $4,916 | $69 |
| Destruction of precancer skin growth, 1 growth | 85 | $4,817 | $39 |
See all 11 services
| Short return visit (20+ min) | 106 | $9,778 | $69 |
| Return visit (30+ min) | 67 | $9,151 | $92 |
| Destruction of skin growth, 1-14 growths | 62 | $7,060 | $89 |
| Biopsy of related skin growth, first growth | 56 | $4,916 | $69 |
| Destruction of precancer skin growth, 1 growth | 85 | $4,817 | $39 |
| Destruction of precancer skin growth, 15 or more growths | 16 | $2,944 | $140 |
| New patient visit (45+ min) | 23 | $2,632 | $114 |
| Destruction of precancer skin growth, 2-14 growths | 64 | $2,296 | $6 |
| New patient visit (30+ min) | 25 | $2,288 | $92 |
| Short return visit | 36 | $2,163 | $45 |
| Biopsy of related skin growth, each additional growth | 19 | $952 | $41 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 309 | More than 82% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 76 | More than 73% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 40 | – | – | 101 | 475 | 396 |
| Destruction of precancer skin growth, 1 growth | 32 | 18 | 18 | 48 | 118 | 123 |
| Destruction of skin growth, 1-14 growths | 24 | – | 15 | 33 | 69 | 79 |
| Biopsy of related skin growth, first growth | 64 | 15 | – | 17 | 42 | 71 |
| Punch biopsy, first skin growth | 28 | 13 | 33 | 43 | 43 | – |
| Biopsy of related skin growth, each additional growth | 27 | – | – | – | 12 | 23 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
207 Original Medicare patients in 2024. Average age 72 · Under 65 7% · 85 and older 7% · Women 54% · Also on Medicaid 16% · Health risk score 1.14. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 60% · Diabetes 24% · Chronic kidney disease 18% · Coronary heart disease 17% · Depression 17% · Cancer 15% · Atrial fibrillation 13% · COPD 11% · Heart failure 8% · Stroke 6%.
The office billed $180,621, Medicare allowed $84,194 and paid $59,176; for 1,618 services of 36 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 207 | 1,618 | 72 | 1.14 | $180,621 | $59,176 |
| 2023 | 224 | 1,692 | 73 | 1.01 | $206,945 | $71,350 |
| 2022 | 161 | 1,534 | 74 | 1.02 | $139,714 | $49,749 |
| 2021 | 109 | 849 | 73 | 0.97 | $73,117 | $30,163 |
| 2020 | 113 | 1,038 | 71 | 1.13 | $40,318 | $16,128 |
| 2019 | 173 | 1,861 | 72 | 1.05 | $85,670 | $40,341 |
| 2018 | 48 | 883 | 73 | 0.92 | $24,510 | $11,973 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 82 | $15,836 | $98 |
| Short return visit (20+ min) | 79 | $7,009 | $72 |
| Destruction of skin growth, 1-14 growths | 54 | $6,839 | $99 |
| Destruction of precancer skin growth, 1 growth | 74 | $5,173 | $44 |
| Punch biopsy, first skin growth | 38 | $4,291 | $100 |
| New patient visit (30+ min) | 47 | $3,363 | $72 |
| Biopsy of related skin growth, first growth | 38 | $3,130 | $75 |
| New patient visit (45+ min) | 30 | $2,932 | $98 |
| Destruction of precancer skin growth, 2-14 growths | 59 | $2,882 | $6 |
| Short return visit | 36 | $2,230 | $50 |
| New patient visit (15+ min) | 19 | $845 | $44 |
| Biopsy of related skin growth, each additional growth | 11 | $526 | $44 |
2022: 14 services
| Return visit (30+ min) | 62 | $11,030 | $105 |
| Punch biopsy, first skin growth | 41 | $4,809 | $112 |
| New patient visit (45+ min) | 37 | $4,577 | $124 |
| Short return visit (20+ min) | 45 | $3,405 | $65 |
| New patient visit (30+ min) | 41 | $3,377 | $82 |
| Destruction of skin growth, 1-14 growths | 26 | $3,196 | $97 |
| Long return visit (40+ min) | 15 | $2,572 | $161 |
| Short return visit | 34 | $2,509 | $49 |
| Destruction of precancer skin growth, 1 growth | 38 | $2,215 | $46 |
| Biopsy of related skin growth, first growth | 16 | $1,245 | $73 |
| Punch biopsy, each additional skin growth | 12 | $1,002 | $56 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $942 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $624 | $6 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $71 | None |
2021: 9 services
| Short return visit (20+ min) | 40 | $4,433 | $82 |
| Punch biopsy, first skin growth | 29 | $4,020 | $122 |
| Return visit (30+ min) | 28 | $3,889 | $105 |
| New patient visit (30+ min) | 35 | $3,074 | $88 |
| New patient visit (45+ min) | 21 | $2,803 | $133 |
| Short return visit | 20 | $1,434 | $51 |
| Destruction of skin growth, 1-14 growths | 12 | $1,407 | $94 |
| Destruction of precancer skin growth, 1 growth | 15 | $906 | $50 |
| New patient visit (15+ min) | 11 | $729 | $66 |
2020: 8 services
| Return visit (30+ min) | 33 | $2,028 | $56 |
| Short return visit (20+ min) | 34 | $2,016 | $54 |
| Punch biopsy, first skin growth | 12 | $1,428 | $110 |
| New patient visit (30+ min) | 18 | $1,254 | $70 |
| Short return visit | 19 | $826 | $28 |
| Destruction of precancer skin growth, 1 growth | 17 | $762 | $42 |
| Biopsy of related skin growth, first growth | 14 | $762 | $51 |
| New patient visit (15+ min) | 17 | $683 | $40 |
2019: 13 services
| Return visit (30+ min) | 70 | $6,986 | $72 |
| Test for allergy using skin patch | 14 | $4,860 | $4 |
| Biopsy of related skin growth, first growth | 55 | $4,277 | $67 |
| Short return visit (20+ min) | 53 | $3,905 | $54 |
| New patient visit (15+ min) | 64 | $3,005 | $47 |
| Punch biopsy, first skin growth | 24 | $2,575 | $92 |
| Destruction of skin growth, 1-14 growths | 14 | $1,867 | $78 |
| Short return visit | 30 | $1,467 | $33 |
| New patient visit (30+ min) | 17 | $1,245 | $73 |
| Destruction of precancer skin growth, 1 growth | 25 | $1,177 | $37 |
| Biopsy of related skin growth, each additional growth | 19 | $1,084 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 17 | $132 | $3 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $97 | None |
2018: 5 services
| Return visit (30+ min) | 18 | $1,979 | $82 |
| Short return visit (20+ min) | 19 | $1,840 | $56 |
| Biopsy of single growth of skin and/or tissue | 16 | $1,336 | $74 |
| New patient visit (30+ min) | 14 | $935 | $67 |
| New patient visit (15+ min) | 12 | $687 | $57 |
Medicaid work
$225 in 2023
Medicaid paid $225 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $225 |
| 2023 | 12 | 1 | 12 | $225 |
Drugs they prescribed that Part D paid
$127,203
Pharmacies billed $127,203 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 298) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
281 generic and 17 brand-name prescriptions · $127,203 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Otezla | 11 | $49,690 | $4,517 |
| Clobetasol Propionate | 23 | $970 | $42 |
| Fluorouracil | 15 | $723 | $48 |
| Ketoconazole | 35 | $451 | $13 |
| Triamcinolone Acetonide | 64 | $450 | $7 |
See all 9 drugs
| Otezla | 11 | $49,690 | $4,517 |
| Clobetasol Propionate | 23 | $970 | $42 |
| Fluorouracil | 15 | $723 | $48 |
| Ketoconazole | 35 | $451 | $13 |
| Triamcinolone Acetonide | 64 | $450 | $7 |
| Mometasone Furoate | 12 | $303 | $25 |
| Minoxidil | 20 | $162 | $8 |
| Hydrocortisone | 13 | $40 | $3 |
| Prednisone | 12 | $22 | $2 |
Year by year
| 2024 | 298 | 125 | 0% (0) | 6% | $127,203 |
| 2023 | 456 | 204 | 0% (0) | 9% | $167,821 |
| 2022 | 281 | 127 | None | 4% | $18,999 |
| 2021 | 157 | 94 | None | None | $8,849 |
| 2020 | 116 | 67 | 0% (0) | None | $4,907 |
| 2019 | 161 | 96 | 0% (0) | 10% | $9,914 |
| 2018 | 47 | 30 | None | None | $2,407 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Otezla | 13 | $64,545 | $4,965 |
| Clobetasol Propionate | 53 | $3,315 | $63 |
| Fluorouracil | 42 | $3,246 | $77 |
| Desoximetasone | 14 | $1,177 | $84 |
| Ketoconazole | 50 | $1,058 | $21 |
| Metronidazole | 17 | $795 | $47 |
| Triamcinolone Acetonide | 72 | $660 | $9 |
| Mometasone Furoate | 27 | $605 | $22 |
| Desonide | 14 | $570 | $41 |
| Betamethasone Dipropionate | 17 | $345 | $20 |
| Minoxidil | 12 | $169 | $14 |
| Prednisone | 12 | $77 | $6 |
2022: 8 drugs
| Clobetasol Propionate | 46 | $3,350 | $73 |
| Fluorouracil | 36 | $3,208 | $89 |
| Desoximetasone | 15 | $929 | $62 |
| Ketoconazole | 43 | $895 | $21 |
| Desonide | 12 | $784 | $65 |
| Betamethasone Dipropionate | 18 | $601 | $33 |
| Mometasone Furoate | 13 | $357 | $27 |
| Triamcinolone Acetonide | 23 | $182 | $8 |
2021: 3 drugs
| Fluorouracil | 37 | $3,883 | $105 |
| Ketoconazole | 29 | $816 | $28 |
| Triamcinolone Acetonide | 19 | $217 | $11 |
2020: 3 drugs
| Fluorouracil | 13 | $1,653 | $127 |
| Triamcinolone Acetonide | 29 | $446 | $15 |
| Ketoconazole | 15 | $400 | $27 |
2019: 3 drugs
| Fluorouracil | 22 | $4,512 | $205 |
| Doxycycline Monohydrate | 22 | $532 | $24 |
| Triamcinolone Acetonide | 30 | $390 | $13 |
2018: 1 drug
| Triamcinolone Acetonide | 15 | $245 | $16 |
Money from drug and device companies
$48 in 2025
| 2025 | 2 | 3 | None | $48 |
| 2024 | 2 | 2 | None | $29 |
| 2023 | 3 | 4 | None | $295 |
| 2022 | 2 | 3 | None | $59 |
| 2019 | 2 | 2 | None | $38 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $34 | 2 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $15 | 1 payment
|
See all 3 published payments
| Abbvie | Meals · 2025-09-05 | Skyrizi | $17 |
| Abbvie | Meals · 2025-05-29 | Skyrizi | $17 |
| Xeris Pharmaceuticals | Meals · 2025-01-16 | Gvoke Hypopen | $15 |
See earlier years (2024, 2023, 2022, 2019)
2024: $29
| E.R. Squibb & Sons L.L.C. | Sotyktu | $15 | 1 payment
|
| Dermavant Sciences | Vtama | $14 | 1 payment
|
2023: $295
| E.R. Squibb & Sons L.L.C. | Sotyktu | $150 | 1 payment
|
| Ucb | Bimzelx | $93 | 2 payments
|
| Incyte | Opzelura | $52 | 1 payment
|
2022: $59
| Allergan | None | $46 | 2 payments
|
| Abbvie | Skyrizi | $13 | 1 payment
|
2019: $38
| Regeneron Healthcare Solutions | Dupixent | $24 | 1 payment
|
| Pfizer | Eucrisa | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 82.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972594893
- Licence
- CA A84038, OH 35.133591California A84038: Current · expires 2028-10-31
- Trained
- Harvard Medical School, 2002 · 24 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 23501 Cinema Dr Ste 111, Valencia, CA, 91355
- NPI first listed
- 2005-10-31
- NPI last updated
- 2026-06-09
- NPI record certified
- 2026-06-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 307 Boatner Rd, Eglin Afb, FL, 32542